Five Prime Therapeutics Inc (NASDAQ:FPRX)

During the Trading Day
25.89 +0.97 / +3.89%
As of 3:59pm ET
Day’s Change
During After-Hours   Switch to standard view »
25.15 -0.74 / -2.84%
Volume: 2.7K
Health Technology

Company Description

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. The company advanced product candidates includes, FPA008, FPA144 and FP-1039/GSK3052230. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric (stomach) cancer. The FP-1039/GSK3052230 is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors. Five Prime Therapeutics was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, CA.

Contact Information

Five Prime Therapeutics, Inc.
Two Corporate Drive
South San Francisco California 94080-7047
P:(415) 365-5600
Investor Relations:
(415) 365-5750



Other institutional42.41%
Mutual fund holders26.30%
Individual stakeholders10.06%

Top Executives

Lewis T. WilliamsPresident, Chief Executive Officer & Director
Marc L. BelskyChief Financial Officer & Senior Vice President
Julie HambletonChief Medical Officer & Senior Vice President
Aron M. KnickerbockerDirector, Chief Business Officer & Senior VP
Francis Willard SarenaSecretary, Senior Vice President & General Counsel

To view my watchlist

Not a member yet?

Sign up now for a free account